🟢 Veraxa Biotech is trading 11% up today after first in vivo BiTAC-ADC proof-of-concept data

Veraxa Biotech is trading at $1.28, up 10.53%, after presenting first in vivo proof-of-concept data for its BiTAC-ADC platform on October 13.

• In a breast cancer model, a single dose produced strong tumor regression.
• The treatment arm showed no body-weight decrease; the announcement described a selective tumor response and potential safety advantages.
• The announcement did not report stock activity or volume; trading-volume details are unavailable.